Company / Net Income
ENANTA PHARMACEUTICALS INC Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$133.8M
FY2025
5-year range
-$133.8M / $46.4M
FY2021-FY2025
Trend
-9.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income has declined for 5 consecutive years, from $72M in FY2020 to -$134M in FY2025.
Based on SEC 10-K filings.
-$134M in FY2025.
Declined from -$79M to -$134M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- ENANTA PHARMACEUTICALS INC's net income has declined for 5 consecutive years.
- In FY2025, net income decreased 9.9% year-over-year.
- Peak net income was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$133.8M | -9.9% |
| FY2024 | -$121.8M | -54.1% |
| FY2023 | -$79.0M | -118.4% |
| FY2022 | -$36.2M | -178.0% |
| FY2021 | $46.4M | -35.5% |
| FY2020 | $72.0M | +306.3% |
| FY2019 | $17.7M | -18.3% |
| FY2018 | $21.7M | -72.6% |
| FY2017 | $79.0M | +129.4% |
| FY2016 | $34.4M | +257.7% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026